Filtered By:
Condition: Thrombosis
Procedure: Coronary Angioplasty

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 869 results found since Jan 2013.

Efficacy and safety of direct oral anticoagulants in the treatment of left ventricular thrombus after acute anterior myocardial infarction in patients who underwent percutaneous coronary intervention
CONCLUSIONS: DOACs appears to be a suitable alternative to warfarin for the management of LVT post STEMI, especially in patients who are intolerant to warfarin.PMID:36200193 | DOI:10.2174/1570161120666221003104821
Source: Current Vascular Pharmacology - October 6, 2022 Category: Drugs & Pharmacology Authors: Jing Liang Zhijian Wang Yujie Zhou Hua Shen Meng Chai Xiaoteng Ma Hongya Han Qiaoyu Shao Qiuxuan Li Source Type: research

Short dual antiplatelet therapy in patients with high bleeding risk undergoing percutaneous coronary intervention: a systematic review and meta-analysis
Conclusions Shortening the DAPT regimen to 1 or 6 months did not increase the risk of MACE, and the 6-month DAPT regimen reduced the risk of major bleeding. However, the 3-month DAPT regimen increased the risk of ischemic stroke. Thus, shortened DAPT reduced the risk of MACE and bleeding, with a small absolute increase in ischemic strokes.
Source: Coronary Artery Disease - October 6, 2022 Category: Cardiology Tags: Reviews in Depth Source Type: research

Comparative efficacy and safety of antiplatelet or anticoagulant therapy in patients with chronic coronary syndromes after percutaneous coronary intervention: A network meta-analysis of randomized controlled trials
Aimed to evaluate and compare the interactive effects of different antiplatelet or anticoagulation strategies in patients with chronic coronary syndromes (CCS) after percutaneous coronary intervention (PCI). Randomized controlled trials comparing different antiplatelet or anticoagulant strategies in patients with CCS after PCI were included. The primary outcomes were major adverse cardiovascular event (MACE), mortality, ischemic and bleeding events. Compared to aspirin alone, addition of prasugrel or ticagrelor to aspirin resulted in lower risk of myocardial infarction (MI) [odds ratio (OR): 0.38 (95% confidence interval 0...
Source: Frontiers in Pharmacology - September 30, 2022 Category: Drugs & Pharmacology Source Type: research

Prognostic Impact of Renal Dysfunction at 1-Year Follow-Up on Clinical Outcomes After Percutaneous Coronary Intervention
CONCLUSION: Persistent and new-onset renal dysfunction at 1-year follow-up were associated with unfavorable outcomes in patients with CAD who underwent PCI.PMID:36123047 | DOI:10.5551/jat.63746
Source: Journal of Atherosclerosis and Thrombosis - September 19, 2022 Category: Cardiology Authors: Tetsuya Takahashi Tetsu Watanabe Tomonori Aono Yoichiro Otaki Masahiro Wanezaki Satoshi Nishiyama Daisuke Kutsuzawa Shigehiko Kato Harutoshi Tamura Takanori Arimoto Hiroki Takahashi Masafumi Watanabe Source Type: research

Anti-Atherosclerotic Therapies: Milestones, Challenges, and Emerging Innovations
Mol Ther. 2022 Sep 4:S1525-0016(22)00553-6. doi: 10.1016/j.ymthe.2022.08.024. Online ahead of print.ABSTRACTAtherosclerosis is the main underlying pathology for many cardiovascular diseases (CVD) which are the leading cause of death globally and represent a serious health crisis. Atherosclerosis is a chronic condition that can lead to myocardial infarction, ischemic cardiomyopathy, stroke, and peripheral arterial disease. Elevated plasma lipids, hypertension, and high glucose are the major risk factors for developing atherosclerotic plaques. To date, most pharmacological therapies aim to control these risk factors but do n...
Source: Atherosclerosis - September 6, 2022 Category: Cardiology Authors: Isabella Hetherington Hana Totary-Jain Source Type: research

A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes Following Acute Myocardial Infarction
CONCLUSIONS: In patients with recent acute MI, 3 doses of asundexian, when added to aspirin plus a P2Y12 inhibitor, resulted in dose-dependent, near-complete inhibition of FXIa activity without a significant increase in bleeding and a low rate of ischemic events. These data support the investigation of asundexian at a dose of 50 mg daily in an adequately powered clinical trial of patients following acute MI.PMID:36030390 | DOI:10.1161/CIRCULATIONAHA.122.061612
Source: Circulation - August 28, 2022 Category: Cardiology Authors: Sunil V Rao Bodo Kirsch Deepak L Bhatt Andrzej Budaj Rosa Coppolecchia John Eikelboom Stefan K James W Schuyler Jones Bela Merkely Lars Keller Renicus S Hermanides Gianluca Campo Jos é Luis Ferreiro Taro Shibasaki Hardi Mundl John H Alexander Source Type: research

New permanent bundle-branch block and long-term prognosis of patients with new onset ST-elevation myocardial infarction who underwent percutaneous coronary intervention
Conclusion: New onset permanent RBBB in patients with new onset STEMI who underwent PCI may be correlated independently with increased risk of poor long-term prognosis.
Source: Frontiers in Physiology - August 22, 2022 Category: Physiology Source Type: research

Adverse Impact of Peri-Procedural Stroke in Patients Who Underwent Percutaneous Coronary Intervention
Peri-procedural stroke (PPS) is an important complication in patients who underwent percutaneous coronary intervention (PCI). The extent to which PPS impacts mortality and outcomes remains to be defined. Consecutive patients who underwent PCI enrolled in the Victorian Cardiac Outcomes Registry (2014 to 2018) were categorized into PPS and no PPS groups. The primary outcome was 30-day major adverse cardiovascular events (MACEs) (composite of mortality, myocardial infarction, stent thrombosis, and unplanned revascularization).
Source: The American Journal of Cardiology - August 20, 2022 Category: Cardiology Authors: Noah Z. Wexler, Sara Vogrin, Angela L. Brennan, Samer Noaman, Omar Al-Mukhtar, Kawa Haji, Jason E. Bloom, Diem T. Dinh, Wayne C. Zheng, James A. Shaw, Stephen J. Duffy, Jeffrey Lefkovits, Christopher M. Reid, Dion Stub, David M. Kaye, Nicholas Cox, Willia Source Type: research

Paradoxical Long-Term Impact Between Serum Apolipoprotein E and High-Density Lipoprotein Cholesterol in Patients Undergoing Percutaneous Coronary Intervention
CONCLUSIONS: Serum ApoE levels may have a paradoxical impact on the future cardiovascular risk depending on the HDL-C status in patients with CAD.PMID:35934781 | DOI:10.5551/jat.63535
Source: Journal of Atherosclerosis and Thrombosis - August 7, 2022 Category: Cardiology Authors: Tatsuya Fukase Tomotaka Dohi Ryota Nishio Mitsuhiro Takeuchi Norihito Takahashi Yuichi Chikata Hirohisa Endo Shinichiro Doi Hiroki Nishiyama Iwao Okai Hiroshi Iwata Shinya Okazaki Katsumi Miyauchi Hiroyuki Daida Tohru Minamino Source Type: research